DIDEO

IRI:
http://purl.obolibrary.org/obo/dideo.owl
Version IRI:
http://purl.obolibrary.org/obo/dideo/release/2023-10-16/dideo.owl
Current version :
2023-10-16
Authors :
Mathias Brochhausen
Contributors :
Anuj Shah
Dan Malone
Jessica Tay-Sontheimer
Jingjing Yu
Jodi Schneider
Philip E. Empey
Richard D. Boyce
William R. Hogan
Imported Ontologies :
http://purl.obolibrary.org/obo/bfo/2014-05-03/classes-only.owl (visualise it with LODE )
http://purl.obolibrary.org/obo/iao/2017-03-24/iao.owl (visualise it with LODE )
http://purl.obolibrary.org/obo/ro/core.owl (visualise it with LODE )
Other visualisation :
Ontology source - WebVowl

Abstract

The Drug-drug Interaction and Drug-drug Interaction Evidence Ontology (DIDEO) by the DIDEO development group is licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

Table of Content

  1. Classes
  2. Object Properties
  3. Data Properties
  4. Named Individuals
  5. Annotation Properties
  6. Namespace Declarations

Classes

1-benzofuransc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38830

has super-classes
benzofuransc
has sub-classes
amiodaronec

17alpha-estradiol 3-glucosiduronic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_15822

has super-classes
organooxygen compoundc

293 transfected cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000189

Immortalized human kideny cells transfected/transduced with a transporter or enzyme; an in vitro model overexpressing transporter or enzyme of interest; used for transporter or metabolism assays
is equivalent to
293-derived cellc and (is_specified_output_ofop some transfectionc)
has super-classes
293-derived cellc

293-derived cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0037237

has super-classes
cell line cellc
has sub-classes
293 transfected cellc

3'-phospho-5'-adenylyl sulfatec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_17980

has super-classes
esterc

4'-hydroxydiclofenacc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_59613

has super-classes
organic cyclic compoundc

4-hydroxytolbutamidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63799

has super-classes
organic cyclic compoundc

5'-hydroxyomeprazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63840

has super-classes
benzimidazolesc

5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetatec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_82814

has super-classes
benzothiazepinec
has sub-classes
diltiazemc

6-hydroxypaclitaxelc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_63859

has super-classes
organic molecular entityc

6beta-hydroxytestosteronec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34477

has super-classes
organooxygen compoundc

7-ethoxyresorufinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34480

has super-classes
phenoxazinec

7-ethoxyresorufin O-deethylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000172

O-deethylation of 7-Ethoxyresorufin to form resorufin; probe substrate of CYP1A activity
is equivalent to
deethylationc and (has inputop some 7-ethoxyresorufinc) and (has outputop some resorufinc)
has super-classes
deethylationc

absorbabilityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000034

has super-classes
b f o 0000016

absorbability measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000036

is equivalent to
is_specified_output_ofop some drug absorbability assayc
has super-classes
i a o 0000032c
i a o 0000136op some drug productc

absorption of materialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHMO_0002914

Gold Book, somewhat modified. It goes on "The process of one material (absorbate) being retained by another (absorbent); this may be the physical solution of a gas, liquid, or solid in a liquid, attachment of molecules of a gas, vapour, liquid, or dissolved substance to a solid surface by physical forces, etc."
has super-classes
b f o 0000015

active ingredientc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000028

has super-classes
role of scattered molecular aggregatec
b f o 0000054 only b f o 0000015 and (has partop some drug administrationc) and (has partop some b f o 0000015 and (has participantop some scattered molecular aggregatec) and (has participantop some organismc))

active ingredient quantification specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000124

has super-classes
dose quantification specificationc

adverse drug eventc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000005

has super-classes
adverse eventc
has sub-classes
causal adverse drug eventc

adverse drug reaction causality evaluation protocolc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000087

has super-classes
protocolc

adverse eventc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000001

has super-classes
pathological bodily processc
has sub-classes
adverse drug eventc, severe adverse eventc

alkaline earth coordination entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35217

has super-classes
main-group coordination entityc
has sub-classes
magnesium coordination entityc

amiodaronec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_2663

has super-classes
1-benzofuransc

anatomical systemc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0000467

has super-classes
material anatomical entityc
has sub-classes
digestive systemc

area under curvec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/STATO_0000209

has super-classes
i a o 0000109c
has sub-classes
pharmacokinetic area under curvec

area under the curve ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000093

has super-classes
pharmacokinetic parameter ratioc

assayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000070

has super-classes
o b i 0000011c
has sub-classes
clinical studyc, drug absorbability assayc, drug bioavailability assayc, drug first pass metabolism assayc, drug maximum concentration assayc, genotypingc, phenotype characterizationc

atorvastatinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_39548

has super-classes
dihydroxy monocarboxylic acidc

azolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_68452

has super-classes
monocyclic heteroarenec
has sub-classes
diazolec, triazolec

baculovirus-insect recombinant protein production host cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000168

Insect cell-hosted viral system used to produce and express recombinant proteins/enzymes; these systems are used in metabolism studies
has super-classes
cultured cellc

benzimidazolesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_22715

has super-classes
organic heterobicyclic compoundc
has sub-classes
5'-hydroxyomeprazolec

benzofuransc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35259

has super-classes
organic heteropolycyclic compoundc
has sub-classes
1-benzofuransc, Bufuralolc

benzothiazepinec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_48684

has super-classes
organic heterobicyclic compoundc
has sub-classes
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetatec

bioavailabilityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000010

has super-classes
b f o 0000016
inheres inop some drug productc

bioavailability measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000025

is equivalent to
is_specified_output_ofop some drug bioavailability assayc
has super-classes
i a o 0000032c
i a o 0000136op some drug productc

bioavailability ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000102

has super-classes
pharmacokinetic parameter ratioc

biological regulationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0065007

has super-classes
biological_processc
has sub-classes
negative regulation of metabolic processc, regulation of biological processc

biological rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24432

has super-classes
b f o 0000023
has sub-classes
inhibitorc

biological_processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0008150

has super-classes
b f o 0000015
has sub-classes
biological regulationc, cellular processc, drug-drug interactionc, drug-drug interaction effectc, gastrointestinal functioningc, gene expressionc, localizationc, metabolic processc, pharmacokinetic processc

biomacromoleculec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33694

has super-classes
macromoleculec
has sub-classes
information biomacromoleculec

bodily processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000060

has super-classes
b f o 0000015
has sub-classes
molecular_functionc, pathological bodily processc

breaking of covalent bondc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000780

has super-classes
molecular processc
has sub-classes
deethylationc, demethylationc

Bufuralolc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_34593

has super-classes
benzofuransc

bufuralol 1'-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000174

1'-hydroxylation of bufuralol to form 1'-hydroxybufurolol; probe substrate of CYP2D6 activity
has super-classes
hydroxylationc

bupropionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_3219

has super-classes
organic cyclic compoundc

bupropion hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000176

Hydroxylation of bupropion at the 1 position to form 1-hydroxybupropion; probe substrate of CYP2B6 activity
has super-classes
hydroxylationc

Caco-2 cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0002172

disease: colorectal adenocarcinoma
has super-classes
cell line cellc
has sub-classes
siRNA knockout Caco-2 cellc

carbon group molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33582

has super-classes
p-block molecular entityc
has sub-classes
organic molecular entityc

carbon oxoacidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35605

has super-classes
organooxygen compoundc
has sub-classes
carboxylic acidc

carboxylic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33575

has super-classes
carbon oxoacidc
has sub-classes
hydroxy carboxylic acidc

carboxylic esterc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33308

has super-classes
esterc
has sub-classes
lactonec

catalytic activityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0003824

has super-classes
molecular_functionc
is in domain of
realizes substrate roleop

causal adverse drug eventc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000095

has super-classes
adverse drug eventc

cell linec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0000031

The term 'line' is used when a culture has undergone an intentional experimental process to establish a more uniform and stable population of cells (see 'establishing cell line'). This will require one or more passages, but may involve additional selection processes. Through such passaging and/or selection processes, the resulting 'line' attains some level of genetic stability and compositional homogeneity which is typically absent in primary cultures. Because of their relative homogeneity, ‘lines’ are capable of being characterized and stably propagated over a period of time. A new *type* of cell line can be established not only through the passaging/selection of a primary culture, but also through experimental modifications of existing lines (e.g. immortalization, stable genetic modifications, drug selection for a resistant subset, etc.). The definition provided here establishes the 'scale' of cell populations that qualify as cell lines - specifically those with a shared propagation history in culture. In this way, the 'cell line' class demarcates populations that represent what researchers actually use in the practice of science - e.g. as inputs to culturing, experimentation, and sharing. The definition is such that cell lines will exhibit important attributes. For example, they will have a relatively homogenous cell type composition as they have experienced similar selective pressures due to their continuous co-propagation. In addition, these populations can also be characterized by a passage number, again owing to their common passaging history.  As defined here, 'cell line' can refer to a population of cells in active culture, applied experimentally, or stored in a quiescent state for future use.
has super-classes
cultured cell populationc

cell line cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0000001

A 'cell line cell' is a part of a cell line established through the passaging/selection of a primary cultured cells or the experimental modification of an existing cell line. New types of cell line cells are established after sufficient passaging of a primary culture to establish a stable and homogenous population that qualifies as a line (typically 1-20 passages), or following some spontaneous or experimental modification that confers novel characteristics to an existing line. A cell line cell typically has mutations of five or more genes compared to the original cell that derives the cell line cell. Some gene mutations may turn on some oncogenes. Cell line cells can be in active culture, stored in a quiescent state for future use (e.g. frozen in liquid nitrogen), or applied in experimental procedures.
has super-classes
cultured cellc
has sub-classes
293-derived cellc, CHO cellc, Caco-2 cellc, Fa2N-4 cellc, HBG BC2 cellc, Hep G2 cellc, HepaRG cellc, LLC-PK subscript(1) cellc, MDCK cellc

cell pelletc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_1000024

has super-classes
processed materialc

cellular metabolic processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0044237

has super-classes
metabolic processc

cellular processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0009987

has super-classes
biological_processc

cellular_componentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0005575

Note that, in addition to forming the root of the cellular component ontology, this term is recommended for use for the annotation of gene products whose cellular component is unknown. Note that when this term is used for annotation, it indicates that no information was available about the cellular component of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this.
has super-classes
b f o 0000040
has sub-classes
macromolecular complexc

centrifugationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0302886

has super-classes
material component separationc
has sub-classes
high-speed centrifugationc

centrifuge pellet rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000029

has super-classes
b f o 0000023

chemical entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24431

has super-classes
b f o 0000040
has sub-classes
chemical substancec, molecular entityc

chemical substancec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_59999

has super-classes
chemical entityc
has sub-classes
mixturec

chlorzoxazonec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_3655

has super-classes
organic heterobicyclic compoundc

chlorzoxazone 6-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000197

Hydroxylation of chlorzoxazone at the 6 position to form 6-hydroxychlorzoxazone; probe substrate of CYP2E1 activity
has super-classes
hydroxylationc

CHO cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0002421

has super-classes
cell line cellc
has sub-classes
CHO transfected cellc

CHO transfected cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000186

Chinese hamster ovary cells transfected with human transporter DNA; an in vitro model used to study transporters
is equivalent to
CHO cellc and (is_specified_output_ofop some transfectionc)
has super-classes
CHO cellc

clearance measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000089

has super-classes
i a o 0000109c

clinical drug rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000001

Authors :
William Hogan
has super-classes
b f o 0000023

clinical studyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000124

is equivalent to
assayc and (b f o 0000055 some r o 0000059 some clinical study designc)
has super-classes
assayc

clinical study designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500001

has super-classes
study designc

clinically relevant potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000024

Alternative definitions use the risk of harm instead of the risk of an AE.
has super-classes
potential drug-drug interactionc

containerc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000967

has super-classes
devicec
has sub-classes
microtiter platec

contraindicationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000055

has super-classes
b f o 0000016

coordination entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33240

has super-classes
heteroatomic molecular entityc
has sub-classes
main-group coordination entityc

coumarinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_28794

has super-classes
organic heteropolycyclic compoundc

coumarin 7-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000179

Hydroxylation of coumarin at the 7 position to form 7-hydroxycoumarin; probe substrate of CYP2A6 activity
has super-classes
hydroxylationc

countc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000032

has super-classes
i a o 0000109c
has sub-classes
number of doses in a dayc, number of liver donorsc

cryopreserved human hepatocyte populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000149

Cells isolated from human liver that have been frozen and stored, usually in liquid nitrogen; an in vitro model system for human metabolism or transport; cells can be thawed and used in metabolism or transport assays
has super-classes
cultured cell populationc

cultured cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CL_0000010

Note that this class was re-labeled to 'cultured cell' instead of 'cell line cell', as it intent was clarified to cover any cultured cells of multicellular and unicellular organisms. This includes cells actively being cultured, or cells that have been cultured but are stored in a quiescent state for future use. In having been cultured, cells must establish homeostasis and often replicate in a foreign environment. Accomodation of this stress initiates a selection of cells fit for such challenges, wherein necessary adaptive biochemical and.or genetic changes can occur. These changes can set them apart from the in vivo cells from which they derive, and such changes will typically accumulate and change over increasing time in culture.
has super-classes
experimentally modified cell in vitroc
has sub-classes
E. coli recombinant protein production host cellc, baculovirus-insect recombinant protein production host cellc, cell line cellc

cultured cell populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100060

The extent of a 'cultured cell population' is restricted only in that all cell members must share a propagation history (ie be derived through a common lineage of passages from an initial culture). In being defined in this way, this class can be used to refer to the populations that researchers actually use in the practice of science - ie are the inputs to culturing, experimentation, and sharing. The cells in such populations will be a relatively uniform population as they have experienced similar selective pressures due to their continuous co-propagation. And this population will also have a single passage number, again owing to their common passaging history. Cultured cell populations represent only a collection of cells (ie do not include media, culture dishes, etc), and include populations of cultured unicellular organisms or cultured multicellular organism cells. They can exist under active culture, stored in a quiescent state for future use, or applied experimentally.
has super-classes
processed materialc
has sub-classes
cell linec, cryopreserved human hepatocyte populationc, freshly isolated human hepatocyte populationc, human intestinal epithelial cell populationc, sandwich cultured hepatocyte populationc, transgenic animal hepatocyte populationc

cytochrome P450c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38559

has super-classes
heme-thiolate proteinc
r o 0000085 some catalytic activityc

data item about biological processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000002

is equivalent to
i a o 0000027c and (i a o 0000136op some biological_processc)
has super-classes
i a o 0000027c

data item from extrapolationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000005

has super-classes
i a o 0000027c

deethylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0001385

has_participant: CHEBI:37807
has super-classes
breaking of covalent bondc
has sub-classes
7-ethoxyresorufin O-deethylationc, phenacetin O-deethylationc

dehydrogenationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000590

has super-classes
b f o 0000015
has sub-classes
nifedipine dehydrogenationc

delta-lactonec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_18946

has super-classes
lactonec
has sub-classes
lovastatinc, simvastatinc

demethylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0001364

has_participant: CHEBI:32875
has super-classes
breaking of covalent bondc
has sub-classes
dextromethorphan O-demethylationc

devicec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000968

has super-classes
processed materialc
has sub-classes
containerc

dextromethorphanc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_4470

has super-classes
organic heterotetracyclic compoundc

dextromethorphan O-demethylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000181

O-demethylation of dextromethorphan to form dextrorphan;probe substrate of CYP2C9 activity
is equivalent to
demethylationc and (has inputop some dextromethorphanc) and (has outputop some dextrorphanc)
has super-classes
demethylationc

dextrorphanc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_29133

has super-classes
heteroorganic entityc

diazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23677

has super-classes
azolec
has sub-classes
imidazolesc

diclofenacc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_47381

has super-classes
organic cyclic compoundc

diclofenac 4'-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000182

Hydroxylation of diclofenac to form 4'-hydroxydiclofenac; probe substrate of CYP2C9 activity
has super-classes
hydroxylationc

diclofenac 4'-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000191

Hydroxylation of diclofenac to form 4'-hydroxydiclofenac; probe substrate of CYP2C9 activity
is equivalent to
hydroxylationc and (has inputop some diclofenacc) and (has outputop some 4'-hydroxydiclofenacc)
has super-classes
hydroxylationc

digestive systemc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0001007

has super-classes
anatomical systemc

dihydroxy monocarboxylic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35972

has super-classes
hydroxy monocarboxylic acidc
has sub-classes
atorvastatinc, rosuvastatinc

Dikaryac back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_451864

has super-classes
organismc

diltiazemc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_101278

has super-classes
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetatec

dimensionless unitc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000186

has super-classes
unitc
has sub-classes
ratioc

dose quantification specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000123

has super-classes
i a o 0000030c
has sub-classes
active ingredient quantification specificationc, drug product quantification specificationc

dose specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000969

has super-classes
i a o 0000033c

drug absorbability assayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000035

has super-classes
assayc
o b i 0000293op some absorbabilityc and (inheres inop some drug productc)

drug administrationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000031

has super-classes
treatmentc
treatmentc and (has participantop some drug productc) and (has participantop some organismc)

drug bioavailability assayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000026

has super-classes
assayc
o b i 0000293op some bioavailabilityc

drug co-administrationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000021

An instance of this occurs when at least two or more drugs are taken in a specific time interval and the individual time interval for each drug administration overlaps with the other drug's or drugs' time interval(s). (SG1)
has super-classes
o b i 0000011c

drug concept set identifierc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000128

Term and definition provided by Richard D. Boyce.
has super-classes
identifierc

drug first pass metabolism assayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000032

has super-classes
assayc
o b i 0000293op some first pass effect dispositionc

drug identifierc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000461

has super-classes
identifierc

drug maximum concentration assayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000037

has super-classes
assayc
(o b i 0000293op some drug productc) and (o b i 0000293op some organismc)

drug maximum concentration measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000038

is equivalent to
is_specified_output_ofop some drug maximum concentration assayc
has super-classes
i a o 0000032c

drug maximum concentration ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000099

has super-classes
pharmacokinetic parameter ratioc

drug metabolic processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0017144

has super-classes
metabolic processc

drug package AUC informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000047

is equivalent to
(part ofop some drug package insertc) and (i a o 0000136op some pharmacokinetic area under curvec)
has super-classes
i a o 0000030c

drug package insertc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000044

has super-classes
i a o 0000310c
has sub-classes
U.S. Food and Drug Administration drug labelc

drug productc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000005

Authors :
William Hogan
has super-classes
b f o 0000040

drug product quantification specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PDRO/PDRO.owl#PDRO_0000125

has super-classes
dose quantification specificationc

drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000020

A clinically meaningful alteration in the exposure and/or response to a drug (object drug) that has occurred as a result of the co-administration of another drug (precipitant drug)Oates JA. Chapter 5. Goodman and Gilman 11th ed (2006):117–36; Hines. Response can refer to either precipitating an adverse event or altering the therapeutic effect of the object drug. Although some DDIs may be used for therapeutic benefit, this paper focuses on those with adverse clinical consequences. (based on the 2013 DDI conference series) / has participant some mechanism.
has super-classes
biological_processc
has occurrent partop some drug co-administrationc
has participantop some b f o 0000040
has sub-classes
reported drug-drug interactionc

drug-drug interaction descriptionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000001

has super-classes
i a o 0000030c
i a o 0000136op some drug-drug interactionc
has sub-classes
drug-drug interaction description from drug package insertc

drug-drug interaction description from drug package insertc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000042

has super-classes
drug-drug interaction descriptionc
has sub-classes
drug-drug interaction description from FDA label informationc

drug-drug interaction description from FDA label informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000043

has super-classes
drug-drug interaction description from drug package insertc
part ofop some U.S. Food and Drug Administration drug labelc

drug-drug interaction effectc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000125

is equivalent to
process is result ofop some drug-drug interactionc
has super-classes
biological_processc

drug-drug interaction evidencec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000023

An instance of this type represents a information artifact used to establish knowledge for or against the existence of a drug-drug interaction.
has super-classes
i a o 0000030c
i a o 0000136op some drug co-administrationc

drug-drug interaction management optionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000007

An instance of this entity would represent an optional recommendation for the clinical management of patients who are exposed or about to be exposed to a potential DDI. Management options may be generated by expert opinion, consensus, and/or a review and synthesis of relevant evidence.
has super-classes
i a o 0000104c

E. coli recombinant protein production host cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000169

Prokaryotic in vitro system used to produce and express recombinant proteins/enzymes; these systems are used in metabolism studies
is equivalent to
cultured cellc and Escherichia colic and (r o 0000053op some recombinant protein production host rolec)
has super-classes
cultured cellc

efflux ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000120

has super-classes
pharmacokinetic parameter ratioc

enzymec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000427

has super-classes
b f o 0000040
is in range of
is substrate ofop

enzyme substrate rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IDO_0100872

has super-classes
b f o 0000023
is in range of
realizes substrate roleop

Escherichia colic back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_562

has super-classes
organismc

establishment of localizationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051234

has super-classes
localizationc
has sub-classes
transportc

esterc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35701

has super-classes
organooxygen compoundc
has sub-classes
3'-phospho-5'-adenylyl sulfatec, carboxylic esterc

estradiolc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23965

has super-classes
organic cyclic compoundc

estradiol glucuronosylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000193

Glucuronidation of estradiol to estradiol-3-glucuronide; probe substrate of UGT1A1 activity (used to measure UGT1A1 activity)
has super-classes
glucuronosylationc

evaluant rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000067

has super-classes
b f o 0000023

evidence data itemc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000055

is equivalent to
i a o 0000027c and (part ofop some evidence information content entityc) and (is_specified_output_ofop some assayc)
has super-classes
i a o 0000027c

evidence information content entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000053

has super-classes
i a o 0000030c
has sub-classes
evidence information from CYP450 drug metabolism identification experimentc, evidence information from CYP450 human microsome drug metabolism identification experimentc, evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitorsc, evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitorsc, evidence information from CYP450 human microsome drug metabolism inhibition experimentc, evidence information from CYP450 metabolic enzyme inhibition experimentc, evidence information from CYP450 recombinant drug metabolism identification experimentc, evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitorsc, evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitorsc, evidence information from CYP450 recombinant drug metabolism inhibition experimentc, evidence information from OATP1B1 inhibition experimentc, evidence information from OATP1B1 inhibition experiment using overexpressed cell linesc, evidence information from OATP1B1 transport protein identification experimentc, evidence information from OATP1B1 transport protein identification experiment using overexpressed cell linesc, evidence information from OATP1B3 inhibition experimentc, evidence information from OATP1B3 inhibition experiment using overexpressed cell linesc, evidence information from OATP1B3 transport protein identification experimentc, evidence information from OATP1B3 transport protein identification experiment using overexpressed cell linesc, evidence information from a publicly reported observation-based adverse drug event reportc, evidence information from an evaluated observation-based case-report of a drug interactionc, evidence information from an observation-based case-report of a drug interactionc, evidence information from chemical analytic characterization of materialc, evidence information from chemical analytic metabolomics of materialc, evidence information from clinical studyc, evidence information from drug metabolism identification experimentc, evidence information from drug metabolism induction experimentc, evidence information from drug metabolism inhibition experimentc, evidence information from drug transport protein induction experimentc, evidence information from drug-drug interaction clinical trialc, evidence information from genotyped pharmacokinetic trialc, evidence information from non-randomized drug-drug interaction clinical trialc, evidence information from observation-based adverse drug event reportc, evidence information from observation-based reportc, evidence information from observational drug-drug interaction studyc, evidence information from observational pharmacokinetic studyc, evidence information from observational studyc, evidence information from p-glycoprotein inhibition experimentc, evidence information from p-glycoprotein inhibition experiment using Caco 2 cell linesc, evidence information from p-glycoprotein inhibition experiment using overexpressed cell linesc, evidence information from p-glycoprotein transport protein identification experimentc, evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell linesc, evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell linesc, evidence information from parallel groups drug-drug interaction clinical trial'c, evidence information from pharmacokinetic trialc, evidence information from phenotyped pharmacokinetic trialc, evidence information from randomized drug-drug interaction clinical trialc, evidence information from transport protein identification experimentc, evidence information from transport protein inhibition experimentc

evidence information from a publicly reported observation-based adverse drug event reportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000083

is equivalent to
evidence information content entityc and (part ofop some public adverse event reporting databasec) and (i a o 0000136op some assayc and (causally downstream ofop some adverse drug eventc and (preceded byop some drug administrationc and (has participantop some chemical entityc or drug productc))))
has super-classes
evidence information content entityc

evidence information from an evaluated observation-based case-report of a drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000088

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (causally downstream ofop some adverse drug eventc and (preceded byop some drug administrationc and (has participantop some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (has participantop some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec))))) and (is_specified_output_ofop some o b i 0000011c and (b f o 0000055 some r o 0000059 some adverse drug reaction causality evaluation protocolc))
has super-classes
evidence information content entityc

evidence information from an observation-based case-report of a drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000084

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (causally downstream ofop some adverse drug eventc and (preceded byop some drug administrationc and (has participantop some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (has participantop some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec)))))
has super-classes
evidence information content entityc

evidence information from chemical analytic characterization of materialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005004

has super-classes
evidence information content entityc

evidence information from chemical analytic metabolomics of materialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005005

has super-classes
evidence information content entityc

evidence information from clinical studyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000056

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some chemical entityc or drug productc))
has super-classes
evidence information content entityc

evidence information from CYP450 drug metabolism identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000063

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some cell linec or tissue specimenc))
has super-classes
evidence information content entityc

evidence information from CYP450 human microsome drug metabolism identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000067

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some tissue specimenc and (is_specified_output_ofop some specimen collection processc and (o b i 0000293op some Homo sapiensc))))
has super-classes
evidence information content entityc

evidence information from CYP450 human microsome drug metabolism identification experiment using antibody inhibitorsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000069

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some immunoglobulin complex, circulatingc and (r o 0000053op some inhibitorc)) and (o b i 0000293op some tissue specimenc and (is_specified_output_ofop some specimen collection processc and (o b i 0000293op some Homo sapiensc))))
has super-classes
evidence information content entityc

evidence information from CYP450 human microsome drug metabolism identification experiment using chemical inhibitorsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000068

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some chemical substancec and (not (immunoglobulin complex, circulatingc)) and (r o 0000053op some inhibitorc)) and (o b i 0000293op some tissue specimenc and (is_specified_output_ofop some specimen collection processc and (o b i 0000293op some Homo sapiensc))))
has super-classes
evidence information content entityc

evidence information from CYP450 human microsome drug metabolism inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000081

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some negative regulation of metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some tissue specimenc and (is_specified_output_ofop some specimen collection processc and (o b i 0000293op some Homo sapiensc))))
has super-classes
evidence information content entityc

evidence information from CYP450 metabolic enzyme inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000070

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some negative regulation of metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some cell linec or tissue specimenc))
has super-classes
evidence information content entityc

evidence information from CYP450 recombinant drug metabolism identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000064

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some cell linec) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))))
has super-classes
evidence information content entityc

evidence information from CYP450 recombinant drug metabolism identification experiment using antibody inhibitorsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000066

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some cell linec) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some immunoglobulin complex, circulatingc and (r o 0000053op some inhibitorc)))
has super-classes
evidence information content entityc

evidence information from CYP450 recombinant drug metabolism identification experiment using chemical inhibitorsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000065

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some cell linec) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some cytochrome P450c))) and (o b i 0000293op some chemical substancec and (not (immunoglobulin complex, circulatingc)) and (r o 0000053op some inhibitorc)))
has super-classes
evidence information content entityc

evidence information from CYP450 recombinant drug metabolism inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000080

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some cell linec) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some negative regulation of metabolic processc and (has participantop some cytochrome P450c))))
has super-classes
evidence information content entityc

evidence information from drug metabolism identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000057

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some metabolic processc and (has participantop some (ribonucleic acidc or proteinc) or (has partop some ribonucleic acidc or (proteinc and (r o 0000085 some catalytic activityc)))))) and (o b i 0000293op some cell linec or tissue specimenc))
has super-classes
evidence information content entityc

evidence information from drug metabolism induction experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005000

has super-classes
evidence information content entityc

evidence information from drug metabolism inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000058

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some in vitro designc) and (o b i 0000293op some chemical substancec and ((part ofop some drug productc) or (r o 0000053op some metabolitec)) and (participates inop some negative regulation of metabolic processc and (has participantop some ((ribonucleic acidc or proteinc) or (has partop some ribonucleic acidc or proteinc)) and (r o 0000085 some catalytic activityc)))) and (o b i 0000293op some cell linec or tissue specimenc))
has super-classes
evidence information content entityc

evidence information from drug transport protein induction experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00005002

has super-classes
evidence information content entityc

evidence information from drug-drug interaction clinical trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000071

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec)))
has super-classes
evidence information content entityc

evidence information from genotyped pharmacokinetic trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000076

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some organismc and (participates inop some pharmacokinetic processc) and (participates inop some genotypingc)) and (o b i 0000293op some chemical entityc or drug productc))
has super-classes
evidence information content entityc

evidence information from non-randomized drug-drug interaction clinical trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000072

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (not (has partop value group randomization)) and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec)))
has super-classes
evidence information content entityc

evidence information from OATP1B1 inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000114

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some solute carrier organic anion transporter family member 1B1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from OATP1B1 inhibition experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000115

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some solute carrier organic anion transporter family member 1B1c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from OATP1B1 transport protein identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000107

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some solute carrier organic anion transporter family member 1B1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from OATP1B1 transport protein identification experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000109

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some solute carrier organic anion transporter family member 1B1c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from OATP1B3 inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000117

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some solute carrier organic anion transporter family member 1B3c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from OATP1B3 inhibition experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000116

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some solute carrier organic anion transporter family member 1B3c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from OATP1B3 transport protein identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000108

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some solute carrier organic anion transporter family member 1B3c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from OATP1B3 transport protein identification experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000110

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some solute carrier organic anion transporter family member 1B3c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from observation-based adverse drug event reportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000061

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (causally downstream ofop some adverse drug eventc and (preceded byop some drug administrationc and (has participantop some chemical entityc or drug productc))))
has super-classes
evidence information content entityc

evidence information from observation-based reportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000077

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (causally downstream ofop some b f o 0000003))
has super-classes
evidence information content entityc

evidence information from observational drug-drug interaction studyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000079

is equivalent to
evidence information content entityc and (i a o 0000136op some (assayc and (b f o 0000055 some r o 0000059 some observation designc)) and (o b i 0000293op some drug productc and (r o 0000053op some object drug rolec)) and (o b i 0000293op some drug productc and (r o 0000053op some precipitant drug rolec)) and (o b i 0000293op some organismc and (participates inop some pharmacokinetic processc)))
has super-classes
evidence information content entityc

evidence information from observational pharmacokinetic studyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000078

is equivalent to
evidence information content entityc and (i a o 0000136op some (assayc and (b f o 0000055 some r o 0000059 some observation designc)) and (o b i 0000293op some drug productc) and (o b i 0000293op some organismc and (participates inop some pharmacokinetic processc)))
has super-classes
evidence information content entityc

evidence information from observational studyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000062

is equivalent to
evidence information content entityc and (i a o 0000136op some (assayc and (b f o 0000055 some r o 0000059 some observation designc)) and (o b i 0000293op some b f o 0000040))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000111

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein inhibition experiment using Caco 2 cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000112

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some Caco-2 cellc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein inhibition experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000113

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein transport protein identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000104

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein transport protein identification experiment using Caco 2 cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000105

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some Caco-2 cellc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from p-glycoprotein transport protein identification experiment using overexpressed cell linesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000106

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some multidrug resistance protein 1c) and (has participantop some chemical substancec and (part ofop some drug productc)))) and (o b i 0000293op some cell line cellc and (participates inop some overexpressionc)))
has super-classes
evidence information content entityc

evidence information from parallel groups drug-drug interaction clinical trial'c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000073

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (not (has partop value group randomization)) and (b f o 0000055 some r o 0000059 some clinical study designc and (has partop some parallel group designc)) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec)))
has super-classes
evidence information content entityc

evidence information from pharmacokinetic trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000075

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some organismc and (participates inop some pharmacokinetic processc)) and (o b i 0000293op some chemical entityc or drug productc))
has super-classes
evidence information content entityc

evidence information from phenotyped pharmacokinetic trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000103

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some organismc and (participates inop some pharmacokinetic processc) and (participates inop some phenotype characterizationc)) and (o b i 0000293op some chemical entityc or drug productc))
has super-classes
evidence information content entityc

evidence information from randomized drug-drug interaction clinical trialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000074

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (has partop some group randomizationc) and (b f o 0000055 some r o 0000059 some clinical study designc) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some object drug rolec)) and (o b i 0000293op some (chemical entityc or drug productc) and (r o 0000053op some precipitant drug rolec)))
has super-classes
evidence information content entityc

evidence information from transport protein identification experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000059

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some import across plasma membranec and (has participantop some proteinc) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence information from transport protein inhibition experimentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000060

is equivalent to
evidence information content entityc and (i a o 0000136op some assayc and (b f o 0000055 some r o 0000059 some ex vivo designc) and (o b i 0000293op some chemical substancec and (is_specified_output_ofop some negative regulation of transporter activityc and (has participantop some proteinc) and (has participantop some chemical substancec and (part ofop some drug productc)))))
has super-classes
evidence information content entityc

evidence material informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000054

is equivalent to
i a o 0000030c and (part ofop some evidence information content entityc) and (i a o 0000142op some b f o 0000001c and (is_specified_input_ofop some assayc))
has super-classes
i a o 0000030c

ex vivo designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001211

has super-classes
study designc

experimentally modified cell in vitroc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CL_0000578

This class has been re-labeled to imply reference only to in vitro experimentally modified cells, similarly, the definition has been slightly updated to reflect this. 'experimentally modified cell' refers only to cells in vitro, and not modified in vivo/in environment cells. There is currently no class representing unmodified in vitro cells (other than the parent 'cell in vitro'), or a class representing modified native cells. More granular subclassing of experimentally modified cell can be found in ReO. MHB 1.12.12
has super-classes
processed materialc
has sub-classes
cultured cellc

Fa2N-4 cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000158

Fa2N-4 cell line was prepared by immortalizing hepatocytes from a 12 year-old Caucasian female donor with Simian virus 40 large T antigen. The donor was tested negative for CMV, HIV, HBV, and HCV. This cell line was mainly used for major CYP induction studies (including CYP3A4/5, 1A2, 2B6, and 2C9) with limitations. Hepatic transporter expression levels are low.
has super-classes
cell line cellc

first pass effect dispositionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000031

has super-classes
b f o 0000016
inheres inop some drug productc

first pass metabolism measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000033

is equivalent to
is_specified_output_ofop some drug first pass metabolism assayc
has super-classes
i a o 0000032c
i a o 0000136op some drug productc

fluconazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_46081

has super-classes
triazolec

fluvastatinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38561

has super-classes
racematec

foldc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000091

has super-classes
ratioc

formation of covalent bondc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000779

has super-classes
molecular processc
has sub-classes
glucuronosylationc, hydroxylationc

freshly isolated human hepatocyte populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000152

Cells isolated from human liver, never frozen; an in vitro model system for human metabolism or transport; cells can be used in metabolism or transport assays
has super-classes
cultured cell populationc

gastrointestinal functioningc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000006

Physiological activity and functions of the gastrointestinal system as a whole or of any of its parts, including digestion, absorption and eliminating waste.
is equivalent to
b f o 0000055 some b f o 0000034 and (inheres inop some part ofop some digestive systemc)
has super-classes
biological_processc

gene expressionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/INO_0000102

has super-classes
biological_processc
has sub-classes
overexpressionc

gene knock outc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001148

has super-classes
genetic transformationc

genetic transformationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600043

has super-classes
material processingc
has sub-classes
gene knock outc, transfectionc

genotypingc back to ToC or Class ToC

IRI: http://www.ebi.ac.uk/efo/EFO_0000750

has super-classes
assayc

glucuronosylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000156

has_participant: CHEBI:24303
has super-classes
formation of covalent bondc
has sub-classes
estradiol glucuronosylationc, lamotrigine glucuronosylationc

glutathionec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16856

has super-classes
organooxygen compoundc

group assignmentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600015

has super-classes
o b i 0000011c
has sub-classes
group randomizationc

group randomizationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0302900

has super-classes
group assignmentc
has members
group randomizationni
is also defined as
named individual

half maximal effective concentration (EC50)c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001180

has super-classes
i a o 0000032c

half maximal inhibitory concentration (IC50)c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001191

has super-classes
i a o 0000032c

half-life ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000100

has super-classes
pharmacokinetic parameter ratioc

HBG BC2 cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000159

An Immortalized human hepatoma cell line possesses the capacities of being reversibly differentiated in vitro, and of maintaining a relatviely higher mtabolic rate in the differentiated phase. It is mainly used for repeated toxicity evaluation in vitro.
has super-classes
cell line cellc

heme-thiolate proteinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36074

has super-classes
hemoproteinc
has sub-classes
cytochrome P450c

hemoproteinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35137

has super-classes
iron proteinc
has sub-classes
heme-thiolate proteinc

Hep G2 cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000185

HepG2 was derived from a liver hepatocellular carcinoma of a 15 year-old Caucasian male. HepG2 cells secrete a variety of major plasma proteins. They are a suitable in vitro model system for the study of polarized human hepatocytes, with high degree of morphological and functional differentiation in vitro. It can be used for hepatic metabolism, transport, and toxicity evaluations in vitro. It was tested negative for HBV.
has super-classes
cell line cellc
has sub-classes
Hep G2 transfected cellc

Hep G2 transfected cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000187

Well characterized immortalized human liver cancer cell line used as an in vitro model system of metabolism or transport
is equivalent to
Hep G2 cellc and (is_specified_output_ofop some transfectionc)
has super-classes
Hep G2 cellc

HepaRG cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000157

HepaRG cells are terminally differentiated human hepatocellular carcinoma cells that reproducibly express drug-metabolizing enzymes and transporters. They are commonly used for metabolism and transport evaluations in vitro, as they respond and function like primary human hepatocytes across a range of applications.
has super-classes
cell line cellc

hepatic clearance ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000101

has super-classes
pharmacokinetic parameter ratioc

heteroarenec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33833

has super-classes
organic heterocyclic compoundc
has sub-classes
NADc, NADPHc, UDP-alpha-D-glucuronic acidc, monocyclic heteroarenec

heteroatomic molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_37577

has super-classes
polyatomic entityc
has sub-classes
coordination entityc

heteroorganic entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33285

has super-classes
organic molecular entityc
has sub-classes
dextrorphanc, organochalcogen compoundc

high-speed centrifugationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHMO_0002013

has super-classes
centrifugationc

Homo sapiensc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_9606

has super-classes
organismc

human intestinal epithelial cell populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000155

has super-classes
cultured cell populationc

human intestine cytosolic fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000161

Cell cytosol obtained via centrifugation of human enterocytes. It is commonly used to support in vitro evaluation of intestinal cytosolic enzymes in the first-pass metabolism of orally ingested xenobitotics.
has super-classes
processed materialc

human intestine S9 fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000167

A mixture of cell cytosol and microsomes isolated by disruption and centrifugation of human enterocytes. It contains a wide range of drug-metabolizing enzymes and is commonly used for in vitro DMPK studies, including both phase I and phase II xenobiotic metabolism.
has super-classes
processed materialc

human liver cytosolic fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000160

Cell cytosol obtained via centrifugation of human liver cells. It is commonly used to support in vitro DMPK studies related to liver cytsolic enzymes, especially non-CYP enzymes, such as phase I enzyme aldehyde oxidase (AO), phase II enzyme SULT.
has super-classes
processed materialc

human liver S9 fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000162

A mixture of cell cytosol and microsomes isolated by disruption and centrifugation of human liver cells. It contains a wide range of drug-metabolizing enzymes and is commonly used for in vitro DMPK studies, including both phase I and phase II xenobiotic metabolism.
has super-classes
processed materialc

hydroxy carboxylic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24669

has super-classes
carboxylic acidc
has sub-classes
hydroxy monocarboxylic acidc

hydroxy monocarboxylic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35868

has super-classes
hydroxy carboxylic acidc
has sub-classes
dihydroxy monocarboxylic acidc

hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000673

has super-classes
formation of covalent bondc
has sub-classes
bufuralol 1'-hydroxylationc, bupropion hydroxylationc, chlorzoxazone 6-hydroxylationc, coumarin 7-hydroxylationc, diclofenac 4'-hydroxylationc, diclofenac 4'-hydroxylationc, midazolam 1'-hydroxylationc, omeprazole 5-hydroxylationc, paclitaxel 6-alpha hydroxylationc, testosterone 6-beta-hydroxylationc, tolbutamide methylhydroxylationc

identifierc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IAO_0020000

Authors :
Mathias Brochhausen
Sep 29, 2016: The current definition has been amended from the previous version: "A proper name is an information content entity that is the outcome of a dubbing process and is used to refer to one instance of entity shared by a group of people to refer to that individual entity." to more accuratly reflect the necessary and sufficient condition on the class. (MB)
has super-classes
i a o 0000030c
has sub-classes
drug concept set identifierc, drug identifierc

imidazolesc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24780

has super-classes
diazolec
has sub-classes
ketoconazolec

immunoglobulin complexc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0019814

Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
has super-classes
protein complexc
has sub-classes
immunoglobulin complex, circulatingc

immunoglobulin complex, circulatingc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0042571

Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
has super-classes
immunoglobulin complexc

import across plasma membranec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0098739

has super-classes
import into cellc

import into cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0098657

has super-classes
transportc
has sub-classes
import across plasma membranec

in vitro designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001285

has super-classes
study designc

individual human intestinal microsomal fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000163

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from enterocytes from a single human donor. They contain a rich variety of metaboliz enzymes for assessing first-pass metabolism for orally ingested drugs.
has super-classes
processed materialc

individual human liver microsomal fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000165

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from liver cells from a single human donor. They contain a rich variety of metaboliz enzymes (e.g. CYP, UGT, FMO) for assessing drug DMPK in vitro, such as metabolic stability, CYP inhibition, CYP phenotyping, metabolite charaterization, etc.
has super-classes
processed materialc

information about decrease of pharmacokinetic area under the curvec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000051

has super-classes
pharmacokinetic area under curve informationc
i a o 0000136op min 2 pharmacokinetic area under curvec

information about increase of pharmacokinetic area under the curvec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000050

has super-classes
pharmacokinetic area under curve informationc
i a o 0000136op min 2 pharmacokinetic area under curvec

information biomacromoleculec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33695

has super-classes
biomacromoleculec
has sub-classes
polynucleotidec, proteinc

inhibitorc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35222

has super-classes
biological rolec

inhibitory constantc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000122

has super-classes
i a o 0000109c

iron proteinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35136

has super-classes
metalloproteinc
has sub-classes
hemoproteinc

itraconazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6076

has super-classes
triazolec

ketoconazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_48339

has super-classes
imidazolesc

lactonec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25000

has super-classes
carboxylic esterc
has sub-classes
delta-lactonec

lamotrigine glucuronosylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000196

Glucuronidation of lamotrigine; probe substrate of UGT1A4 activity (used to measure UGT1A4 activity)
has super-classes
glucuronosylationc

LLC-PK subscript(1) cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0007331

has super-classes
cell line cellc

localizationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051179

has super-classes
biological_processc
has sub-classes
establishment of localizationc

lovastatinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_40303

has super-classes
delta-lactonec

macromolecular complexc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032991

has super-classes
cellular_componentc
has sub-classes
protein complexc

macromoleculec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33839

has super-classes
polyatomic entityc
has sub-classes
biomacromoleculec

magnesium coordination entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33976

has super-classes
alkaline earth coordination entityc
has sub-classes
magnesium halidec

magnesium dichloridec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6636

has super-classes
magnesium halidec

magnesium halidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_51234

has super-classes
magnesium coordination entityc
has sub-classes
magnesium dichloridec

main group molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33579

has super-classes
molecular entityc
has sub-classes
p-block molecular entityc

main-group coordination entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36562

has super-classes
coordination entityc
has sub-classes
alkaline earth coordination entityc

manufacturer rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000571

has super-classes
b f o 0000023

mass value specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001929

has super-classes
scalar value specificationc

material anatomical entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UBERON_0000465

has super-classes
b f o 0000040
has sub-classes
Portion of body substancec, anatomical systemc

material component separationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0600014

has super-classes
material processingc
has sub-classes
centrifugationc

material entity participant in drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000019

A drug entity that participate in a drug-drug interaction but for which its role is not assignable as a precipitant or object.
is equivalent to
(drug productc or (proper_part_ofop some drug productc)) and (participates inop some drug-drug interactionc)
has super-classes
b f o 0000040

material processingc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000094

has super-classes
o b i 0000011c
has sub-classes
genetic transformationc, material component separationc

MDCK cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CLO_0007646

has super-classes
cell line cellc
has sub-classes
MDCK transfected cellc

MDCK transfected cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000194

Dog cells transfected with human transporter; an in vitro model used to study transporters
is equivalent to
MDCK cellc and (is_specified_output_ofop some transfectionc)
has super-classes
MDCK cellc

mechanism of interaction informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000022

An instance of this entity would represent the biochemical process by which pharmacokinetic or pharmacodynamic DDI is thought to occur.
has super-classes
i a o 0000030c
i a o 0000136op some drug-drug interactionc

metabolic potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000015

is equivalent to
potential drug-drug interactionc and (i a o 0000136op some drug metabolic processc)
has super-classes
potential drug-drug interactionc
has sub-classes
metabolism induction potential drug-drug interactionc, metabolism inhibition potential drug-drug interactionc

metabolic processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0008152

Note that metabolic processes do not include single functions or processes such as protein-protein interactions, protein-nucleic acids, nor receptor-ligand interactions.
has super-classes
biological_processc
has sub-classes
cellular metabolic processc, drug metabolic processc

metabolism induction potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000018

has super-classes
metabolic potential drug-drug interactionc

metabolism inhibition potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000017

has super-classes
metabolic potential drug-drug interactionc

metabolitec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25212

has super-classes
b f o 0000023

metalloproteinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35134

has super-classes
proteinc
has sub-classes
iron proteinc

microtiter platec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000192

has super-classes
containerc

Midazolamc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_6931

has super-classes
organic heterocyclic compoundc

midazolam 1'-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000171

Hydroxylation of midazolam at the 1' position to form 1'-hydroxymidazolam;probe substrate of CYP3A4 activity (used to measure CYP3A4 activity)
has super-classes
hydroxylationc

mixturec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_60004

has super-classes
chemical substancec
has sub-classes
racematec

molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_23367

has super-classes
chemical entityc
has sub-classes
main group molecular entityc, polyatomic entityc

molecular processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MOP_0000543

TODO: needs work, formal definition, etc.
has super-classes
b f o 0000015
has sub-classes
breaking of covalent bondc, formation of covalent bondc

molecular_functionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0003674

Note that, in addition to forming the root of the molecular function ontology, this term is recommended for use for the annotation of gene products whose molecular function is unknown. Note that when this term is used for annotation, it indicates that no information was available about the molecular function of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this.
has super-classes
b f o 0000034
bodily processc
has sub-classes
catalytic activityc

monocyclic heteroarenec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38179

has super-classes
heteroarenec
has sub-classes
azolec

multidrug resistance protein 1c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000001891

has super-classes
proteinc

NADc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_13389

has super-classes
heteroarenec
has sub-classes
NADHc

NADHc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16908

has super-classes
NADc

NADPHc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_16474

has super-classes
heteroarenec

NADPH--cytochrome P450 reductasec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000013030

Category=gene.
has super-classes
proteinc

narrow therapeutic indexc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000016

has super-classes
b f o 0000016
inheres inop some drug productc

negative regulation of biological processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0048519

has super-classes
regulation of biological processc

negative regulation of metabolic processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0009892

is equivalent to
biological regulationc and (negatively regulatesop some metabolic processc)
has super-classes
biological regulationc

negative regulation of transportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051051

has super-classes
regulation of transportc

negative regulation of transporter activityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032410

has super-classes
regulation of transporter activityc

net flux ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000121

has super-classes
pharmacokinetic parameter ratioc

nifedipinec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_7565

has super-classes
organic heterocyclic compoundc

nifedipine dehydrogenationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000173

Dehydrogenation of nifedipine to dehydronifedipine;probe substrate of CYP3A4 activity (used to measure CYP3A4 activity)
has super-classes
dehydrogenationc

nucleic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33696

has super-classes
polynucleotidec
has sub-classes
ribonucleic acidc

nucleic acid reagentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0000630

Placeholder for class to be imported from the Reagent Ontology (ReO).
has super-classes
b f o 0000040
has sub-classes
RNA reagentc

number of doses in a dayc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000184

the frequency of administration of the precipitant during the day
has super-classes
countc

number of liver donorsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000190

Number of individual liver samples used
has super-classes
countc

o b i 0000011c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000011

has super-classes
has participantop some b f o 0000040 and (r o 0000053op some clinical drug rolec)
has sub-classes
assayc, drug co-administrationc, group assignmentc, material processingc, specimen collection processc, treatmentc

object drug informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000011

has super-classes
i a o 0000030c
(i a o 0000136op some object drug rolec) and (i a o 0000136op some drug productc)

object drug rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000012

has super-classes
b f o 0000023

observation designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0300311

has super-classes
study designc

observational data item about drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000003

has super-classes
i a o 0000027c

obsolete_drug-drug interaction effectc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000030

has super-classes
obsolete class

obsolete_evidence information content entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000048

has super-classes
obsolete class

omeprazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_7772

has super-classes
racematec

omeprazole 5-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000175

Hydroxylation of omeprazole at the 5 position to form 5-hydroxyomeprazole; probe substrate of CYP2C19 activity
is equivalent to
hydroxylationc and (has inputop some omeprazolec) and (has outputop some 5'-hydroxyomeprazolec)
has super-classes
hydroxylationc

organic cyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33832

has super-classes
organic moleculec
has sub-classes
4'-hydroxydiclofenacc, 4-hydroxytolbutamidec, bupropionc, diclofenacc, estradiolc, organic heterocyclic compoundc

organic heterobicyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_27171

has super-classes
organic heteropolycyclic compoundc
has sub-classes
benzimidazolesc, benzothiazepinec, chlorzoxazonec

organic heterocyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_24532

has super-classes
organic cyclic compoundc
has sub-classes
Midazolamc, heteroarenec, nifedipinec, organic heteropolycyclic compoundc

organic heteropolycyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38166

has super-classes
organic heterocyclic compoundc
has sub-classes
benzofuransc, coumarinc, organic heterobicyclic compoundc, organic heterotetracyclic compoundc, organic heterotricyclic compoundc

organic heterotetracyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38163

has super-classes
organic heteropolycyclic compoundc
has sub-classes
dextromethorphanc

organic heterotricyclic compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_26979

has super-classes
organic heteropolycyclic compoundc
has sub-classes
phenoxazinec, triazolobenzodiazepinec

organic molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_50860

has super-classes
carbon group molecular entityc
has sub-classes
6-hydroxypaclitaxelc, heteroorganic entityc, organic moleculec, paclitaxelc

organic moleculec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_72695

has super-classes
organic molecular entityc
has sub-classes
organic cyclic compoundc

organismc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100026

has super-classes
b f o 0000040
has sub-classes
Dikaryac, Escherichia colic, Homo sapiensc, Xenopus laevisc

organochalcogen compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36962

has super-classes
heteroorganic entityc
has sub-classes
organooxygen compoundc

organooxygen compoundc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36963

has super-classes
organochalcogen compoundc
has sub-classes
17alpha-estradiol 3-glucosiduronic acidc, 6beta-hydroxytestosteronec, carbon oxoacidc, esterc, glutathionec

overexpressionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/INO_0000114

has super-classes
gene expressionc

p-block molecular entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33675

has super-classes
main group molecular entityc
has sub-classes
carbon group molecular entityc, tolbutamidec

paclitaxelc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_45863

has super-classes
organic molecular entityc

paclitaxel 6-alpha hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000177

Hydroxylation of paclitaxel at the 6-alpha position to form 6-alpha-hydroxypaclitaxel; probe substrate of CYP2C8 activity
has super-classes
hydroxylationc

parallel group designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500006

has super-classes
study designc

pathological bodily processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000061

has super-classes
bodily processc
has sub-classes
adverse eventc

percentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000187

has super-classes
ratioc

percent inhibitionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000170

Percent inhibition: the percent decrease in activity of a transporter or enzyme in the presence of a compound from activity in the control experiment
has super-classes
i a o 0000109c

percentage value specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000127

has super-classes
ratio value specificationc

pharmacokinetic area under curvec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000046

has super-classes
area under curvec
i a o 0000136op some part ofop some drug productc

pharmacokinetic area under curve informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000049

is equivalent to
i a o 0000136op some pharmacokinetic area under curvec
has super-classes
i a o 0000030c
has sub-classes
information about decrease of pharmacokinetic area under the curvec, information about increase of pharmacokinetic area under the curvec

pharmacokinetic interaction signalc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000009

Evidence from a kinetic model that a drug-Y has some effect on the absorption, metabolism and elimination of drug-X.
has super-classes
i a o 0000027c

pharmacokinetic parameter ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000095

has super-classes
i a o 0000030c
i a o 0000136op some pharmacokinetic processc
has value specificationop some value specificationc
has sub-classes
area under the curve ratioc, bioavailability ratioc, drug maximum concentration ratioc, efflux ratioc, half-life ratioc, hepatic clearance ratioc, net flux ratioc, renal clearance ratioc, time to maximum drug concentration ratioc, volume of distribution ratioc

pharmacokinetic parameter ratio decreasec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000097

has super-classes
pharmacokinetic parameter ratio directionalityc

pharmacokinetic parameter ratio directionalityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000092

has super-classes
i a o 0000030c
part ofop some pharmacokinetic parameter ratioc
has sub-classes
pharmacokinetic parameter ratio decreasec, pharmacokinetic parameter ratio increasec

pharmacokinetic parameter ratio increasec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000098

has super-classes
pharmacokinetic parameter ratio directionalityc

pharmacokinetic processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000052

has super-classes
biological_processc

phenacetin O-deethylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000178

O-deethylation of phenacetin to form acetaminophen; probe substrate of CYP1A2 activity
has super-classes
deethylationc

phenotype characterizationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0000923

has super-classes
assayc

phenoxazinec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_25970

has super-classes
organic heterotricyclic compoundc
has sub-classes
7-ethoxyresorufinc, resorufinc

physiological observation from clinical study data itemc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000004

is equivalent to
i a o 0000027c and (i a o 0000136op some biological_processc) and (is_specified_output_ofop some b f o 0000055 some r o 0000059 some clinical study designc)
has super-classes
i a o 0000027c

polyatomic entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36357

has super-classes
molecular entityc
has sub-classes
heteroatomic molecular entityc, macromoleculec

polynucleotidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_15986

has super-classes
information biomacromoleculec
has sub-classes
nucleic acidc

pooled human intestinal microsomal fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000166

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from enterocytes of multiple human donors. They contain a rich variety of metaboliz enzymes for assessing first-pass metabolism for orally ingested drugs.
has super-classes
processed materialc

pooled human liver microsomal fractionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000164

Subcellular fractions, derived from endoplasmic reticulum that has been isolated from liver cells from multiple human donors. They contain a rich variety of metaboliz enzymes (e.g. CYP, UGT, FMO) for assessing drug DMPK in vitro, such as metabolic stability, CYP inhibition, CYP phenotyping, metabolite charaterization, etc.
has super-classes
processed materialc

Portion of body substancec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/FMA_9669

has super-classes
material anatomical entityc
has sub-classes
Portion of plasmac

Portion of plasmac back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/FMA_62970

has super-classes
Portion of body substancec

positive regulation of biological processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0048518

has super-classes
regulation of biological processc

potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000000

has super-classes
i a o 0000030c
i a o 0000030c and (has partop some data item about biological processc or observational data item about drug-drug interactionc or physiological observation from clinical study data itemc or data item from extrapolationc)
(has partop some object drug informationc) and (has partop some precipitant drug informationc)
has partop some drug identifierc
has sub-classes
clinically relevant potential drug-drug interactionc, metabolic potential drug-drug interactionc

precipitant drug informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000014

has super-classes
i a o 0000030c
(i a o 0000136op some precipitant drug rolec) and (i a o 0000136op some drug productc)

precipitant drug rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000013

has super-classes
b f o 0000023

primary metabolic clearance enzyme rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000040

has super-classes
b f o 0000023

primary total clearance enzyme rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000039

has super-classes
b f o 0000023
inheres inop some enzymec

probe subtrate rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000123

has super-classes
b f o 0000023

processed materialc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000047

has super-classes
b f o 0000040
has sub-classes
cell pelletc, cultured cell populationc, devicec, experimentally modified cell in vitroc, human intestine S9 fractionc, human intestine cytosolic fractionc, human liver S9 fractionc, human liver cytosolic fractionc, individual human intestinal microsomal fractionc, individual human liver microsomal fractionc, pooled human intestinal microsomal fractionc, pooled human liver microsomal fractionc

proteinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_36080

has super-classes
information biomacromoleculec
has sub-classes
NADPH--cytochrome P450 reductasec, metalloproteinc, multidrug resistance protein 1c, solute carrier organic anion transporter family member 1B1c, solute carrier organic anion transporter family member 1B3c

protein complexc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0043234

A protein complex in this context is meant as a stable set of interacting proteins which can be co-purified by an acceptable method, and where the complex has been shown to exist as an isolated, functional unit in vivo. Acceptable experimental methods include stringent protein purification followed by detection of protein interaction. The following methods should be considered non-acceptable: simple immunoprecipitation, pull-down experiments from cell extracts without further purification, colocalization and 2-hybrid screening. Interactions that should not be captured as protein complexes include: 1) enzyme/substrate, receptor/ligand or any similar transient interactions, unless these are a critical part of the complex assembly or are required e.g. for the receptor to be functional; 2) proteins associated in a pull-down/co-immunoprecipitation assay with no functional link or any evidence that this is a defined biological entity rather than a loose-affinity complex; 3) any complex where the only evidence is based on genetic interaction data; 4) partial complexes, where some subunits (e.g. transmembrane ones) cannot be expressed as recombinant proteins and are excluded from experiments (in this case, independent evidence is necessary to find out the composition of the full complex, if known). Interactions that may be captured as protein complexes include: 1) enzyme/substrate or receptor/ligand if the complex can only assemble and become functional in the presence of both classes of subunits; 2) complexes where one of the members has not been shown to be physically linked to the other(s), but is a homologue of, and has the same functionality as, a protein that has been experimentally demonstrated to form a complex with the other member(s); 3) complexes whose existence is accepted based on localization and pharmacological studies, but for which experimental evidence is not yet available for the complex as a whole.
has super-classes
macromolecular complexc
has sub-classes
immunoglobulin complexc

protocolc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000272

has super-classes
i a o 0000033c
has sub-classes
adverse drug reaction causality evaluation protocolc

public adverse event reporting databasec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000082

has super-classes
i a o 0000100c

racematec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_60911

has super-classes
mixturec
has sub-classes
fluvastatinc, omeprazolec

ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000190

has super-classes
dimensionless unitc
has sub-classes
foldc, percentc

ratio value specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000126

has super-classes
value specificationc
has sub-classes
percentage value specificationc

recombinant protein production host rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000183

An in vitro system that uses a combination of genetic pieces typically in a plasmid that is incorporated into a host cell which is used to produce the protein of interest
has super-classes
target of material addition rolec

regulation of biological processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0050789

has super-classes
biological regulationc
has sub-classes
negative regulation of biological processc, positive regulation of biological processc, regulation of localizationc

regulation of localizationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032879

has super-classes
regulation of biological processc
has sub-classes
regulation of transportc

regulation of transportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0051049

has super-classes
regulation of localizationc
has sub-classes
negative regulation of transportc, regulation of transporter activityc

regulation of transporter activityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0032409

has super-classes
regulation of transportc
has sub-classes
negative regulation of transporter activityc

renal clearance ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000094

has super-classes
pharmacokinetic parameter ratioc

reported drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000008

An instance of a drug-drug interaction that has been identified in case report or study.
has super-classes
drug-drug interactionc
drug-drug interactionc and (inverse i a o 0000136op some i a o 0000311c)

resorufinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_51602

has super-classes
phenoxazinec

ribonucleic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_33697

has super-classes
nucleic acidc

RNA interference oligonucleotidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001206

Placeholder for class to be imported from the Reagent Ontology (ReO).
has super-classes
RNA oligonucleotidec
has sub-classes
siRNA oligonucleotidec

RNA oligonucleotidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001205

Placeholder for class to be imported from the Reagent Ontology (ReO).
has super-classes
RNA reagentc
has sub-classes
RNA interference oligonucleotidec

RNA reagentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001202

Placeholder for class to be imported from the Reagent Ontology (ReO).
has super-classes
nucleic acid reagentc
has sub-classes
RNA oligonucleotidec

role of scattered molecular aggregatec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000030

is equivalent to
b f o 0000023 and (inheres inop some scattered molecular aggregatec)
has super-classes
b f o 0000023
has sub-classes
active ingredientc

rosuvastatinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38545

has super-classes
dihydroxy monocarboxylic acidc

sandwich cultured hepatocyte populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000154

has super-classes
cultured cell populationc

scalar value specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001931

has super-classes
value specificationc
has sub-classes
mass value specificationc

scattered molecular aggregatec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000576

has super-classes
b f o 0000027c

severe adverse eventc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OAE_0000631

has super-classes
adverse eventc

simvastatinc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_9150

has super-classes
delta-lactonec

siRNA knockout Caco-2 cellc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000188

Caco-2 cells treated with siRNA designed to down-regulate specific enzymes or transporters
is equivalent to
Caco-2 cellc and (is_specified_output_ofop some gene knock outc and (o b i 0000293op some siRNA oligonucleotidec))
has super-classes
Caco-2 cellc

siRNA oligonucleotidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/ERO_0001209

Placeholder for class to be imported from the Reagent Ontology (ReO).
has super-classes
RNA interference oligonucleotidec

solute carrier organic anion transporter family member 1B1c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000015223

Category=gene.
has super-classes
proteinc

solute carrier organic anion transporter family member 1B3c back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PR_000015224

Category=gene.
has super-classes
proteinc

specimenc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100051

has super-classes
b f o 0000040
has sub-classes
tissue specimenc

specimen collection processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000659

has super-classes
o b i 0000011c

study designc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0500000

has super-classes
i a o 0000104c
has sub-classes
clinical study designc, ex vivo designc, in vitro designc, observation designc, parallel group designc

supernatant rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000034

has super-classes
b f o 0000023

target of material addition rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000444

has super-classes
b f o 0000023
has sub-classes
recombinant protein production host rolec

testosterone 6-beta-hydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000180

Hydroxylation of testosterone at the 6-beta position to form 6-beta-hydroxytestosterone; probe substrate of CYP3A4 activity
has super-classes
hydroxylationc

time to maximum drug concentration ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000119

has super-classes
pharmacokinetic parameter ratioc

tissue specimenc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001479

has super-classes
specimenc

tolbutamidec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_27999

has super-classes
p-block molecular entityc

tolbutamide methylhydroxylationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000192

Methyhydroxylation of tolbutamide to form hydroxytolbutamide;probe substrate of CYP2D6 activity
has super-classes
hydroxylationc

transfectionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001152

has super-classes
genetic transformationc

transgenic animal hepatocyte populationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000153

Cells isolated from livers of transgenic animals; an in vitro model system for human metabolism or transport
has super-classes
cultured cell populationc

transportc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0006810

has super-classes
establishment of localizationc
has sub-classes
import into cellc

treatmentc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000090

has super-classes
o b i 0000011c
has sub-classes
drug administrationc

triazolamc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_9674

has super-classes
triazolobenzodiazepinec

triazolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_38597

has super-classes
azolec
has sub-classes
fluconazolec, itraconazolec

triazolobenzodiazepinec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_35501

has super-classes
organic heterotricyclic compoundc
has sub-classes
triazolamc

U.S. Food and Drug Administration drug labelc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000045

has super-classes
drug package insertc

UDP-alpha-D-glucuronic acidc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/CHEBI_17200

has super-classes
heteroarenec

unitc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/UO_0000000

has super-classes
i a o 0000030c
has sub-classes
dimensionless unitc

value specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001933

has super-classes
i a o 0000030c
has sub-classes
ratio value specificationc, scalar value specificationc
is in domain of
has specified valuedp

volume of distribution ratioc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000118

has super-classes
pharmacokinetic parameter ratioc

Xenopus laevisc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/NCBITaxon_8355

has super-classes
organismc

Object Properties

actively participates inop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002217

has super-properties
participates inop

begins_to_exist_duringop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000068

has sub-properties
organismally_begins_to_exist_duringop

capable ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002215

has super-properties
capable of part ofop
has sub-properties
enablesop
has domain
b f o 0000004
has range
b f o 0000015

capable of part ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002216

has super-properties
causal agent inop
has sub-properties
capable ofop
has sub-property chains
capable ofop o part ofop

catalyzes a Phase I or Phase II enzymatic reaction involvingop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000096

causal agent inop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002500

has super-properties
causal relation between material entity and a processop
has sub-properties
capable of part ofop

causal relation between material entitiesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002506

has super-properties
causally related toop
has sub-properties
causally influencesop
has domain
b f o 0000040
has range
b f o 0000040

causal relation between material entity and a processop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002595

has super-properties
causally related toop
has sub-properties
causal agent inop
has domain
b f o 0000040
has range
b f o 0000015

causal relation between processesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002501

has super-properties
causally related toop
has sub-properties
causally downstream of or withinop, causally upstream of or withinop
has domain
b f o 0000003
has range
b f o 0000003

causally downstream ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002404

has super-properties
causally downstream of or withinop

causally downstream of or withinop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002427

has super-properties
causal relation between processesop
has sub-properties
causally downstream ofop, regulated byop

causally influencesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002566

has super-properties
causal relation between material entitiesop
has sub-properties
is substrate ofop
has sub-property chains
enablesop o causally upstream ofop o enabled byop

causally related toop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002410

has super-properties
related via dependence toop
has sub-properties
causal relation between material entitiesop, causal relation between material entity and a processop, causal relation between processesop

causally upstream ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002411

has super-properties
precedesop
causally upstream of or withinop
has sub-properties
immediately causally upstream ofop

causally upstream of or withinop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002418

has super-properties
causal relation between processesop
has sub-properties
causally upstream ofop, regulatesop

directly inhibitsop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002408

has super-properties
negatively regulatesop
immediately causally upstream ofop

enabled byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002333

has super-properties
functionally related toop
is inverse of
enablesop

enablesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002327

has super-properties
capable ofop
is inverse of
enabled byop

ends afterop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002086

X ends_after Y iff: end(Y) before_or_simultaneous_with end(X)
has super-properties
temporally related toop
has sub-properties
preceded byop

ends withop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002230

has super-properties
top object property

functionally related toop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002328

has super-properties
top object property
has sub-properties
enabled byop

has inputop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002233

has super-properties
has participantop
is inverse of
input ofop

has occurrent partop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000117

is defined by
http://purl.obolibrary.org/obo/bfo.owl
has super-properties
top object property

has outputop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002234

has super-properties
has participantop
is inverse of
output ofop

has partop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000051

has super-properties
top object property
has sub-properties
has value specificationop

has participantop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000057

has super-properties
top object property
has sub-properties
has inputop, has outputop

has prototypeop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002214

has super-properties
top object property

has value specificationop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001938

has super-properties
has partop

has_proper_partop back to ToC or Object Property ToC

IRI: http://www.obofoundry.org/ro/ro.owl#has_proper_part

has super-properties
top object property
is inverse of
proper_part_ofop

immediately causally upstream ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002412

has super-properties
immediately precedesop
causally upstream ofop
has sub-properties
directly inhibitsop, indirectly inhibitsop

immediately preceded byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002087

X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y)
has super-properties
preceded byop
has sub-properties
process is result ofop

immediately precedesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002090

X immediately_precedes_Y iff: end(X) simultaneous_with start(Y)
has super-properties
precedesop
has sub-properties
immediately causally upstream ofop
has sub-property chains
ends withop o starts withop

indirectly inhibitsop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002409

has super-properties
immediately causally upstream ofop

inheres inop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000052

has super-properties
top object property

inhibits-catalyzes metabolism ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000090

has sub-property chains
molecularly decreases activity ofop o catalyzes a Phase I or Phase II enzymatic reaction involvingop

input ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002352

has super-properties
participates inop
is inverse of
has inputop

interacts withop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002434

has super-properties
top object property
has sub-properties
molecularly interacts withop

involves substrateop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000086

is organismally immediately preceded byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000029

has super-properties
top object property
is inverse of
organismally immediately precedesop

is substrate ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000041

has super-properties
causally influencesop
has domain
(chemical entityc and (r o 0000053op some metabolitec)) or (part ofop some drug productc)
has range
enzymec

is_specified_input_ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000295

has super-properties
participates inop

is_specified_output_ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000312

has super-properties
participates inop

molecularly controlsop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002448

has super-properties
molecularly interacts withop
has sub-properties
molecularly decreases activity ofop
has sub-property chains
enablesop o regulatesop o enabled byop

molecularly decreases activity ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002449

has super-properties
molecularly controlsop
has sub-property chains
enablesop o directly inhibitsop o enabled byop

molecularly interacts withop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002436

has super-properties
interacts withop
has sub-properties
molecularly controlsop

negatively regulated byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002335

has super-properties
regulated byop

negatively regulatesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002212

has super-properties
regulatesop
has sub-properties
directly inhibitsop
has sub-property chains
ends withop o negatively regulatesop

organismally immediately precedesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000028

has characteristics : transitive

has domain
b f o 0000015
has range
b f o 0000015
is inverse of
is organismally immediately preceded byop

organismally_begins_to_exist_duringop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000027

has super-properties
begins_to_exist_duringop

output ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002353

has super-properties
participates inop
is inverse of
has outputop

part ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000050

has super-properties
top object property

participates inop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000056

has super-properties
top object property
has sub-properties
actively participates inop, input ofop, is_specified_input_ofop, is_specified_output_ofop, output ofop

preceded byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000062

has super-properties
ends afterop
top object property
has sub-properties
immediately preceded byop

precedesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000063

has characteristics : transitive

has super-properties
temporally related toop
has sub-properties
causally upstream ofop, immediately precedesop

process is result ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_1110060

has super-properties
immediately preceded byop

proper_part_ofop back to ToC or Object Property ToC

IRI: http://www.obofoundry.org/ro/ro.owl#proper_part_of

has super-properties
top object property
is inverse of
has_proper_partop

realizes substrate roleop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000085

has super-properties
b f o 0000055
has domain
catalytic activityc
has range
enzyme substrate rolec

regulated byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002334

has super-properties
causally downstream of or withinop
has sub-properties
negatively regulated byop

regulatesop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002211

has super-properties
causally upstream of or withinop
has sub-properties
negatively regulatesop
has domain
b f o 0000015
has range
b f o 0000015
has sub-property chains
regulatesop o part ofop
ends withop o regulatesop

related via dependence toop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002609

has super-properties
top object property
has sub-properties
causally related toop

specifies value ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001927

has super-properties
i a o 0000136op

starts withop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002224

has super-properties
top object property

temporally related toop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002222

A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations.
has super-properties
top object property
has sub-properties
ends afterop, precedesop

Data Properties

has specified valuedp back to ToC or Data Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001937

has domain
value specificationc
has range
real

Named Individuals

group randomizationni back to ToC or Named Individual ToC

IRI: http://purl.obolibrary.org/obo/OBI_0302900

belongs to
group randomizationc
is also defined as
class

Annotation Properties

a a o definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/AAO_definition_citation

alternative_termap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/alternative_term

array express labelap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/ArrayExpress_label

b i l a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/BILA_definition_citation

b t o definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/BTO_definition_citation

BFO CLIF specification labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000180

BFO OWL specification labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000179

c a l o h a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/CALOHA_definition_citation

Cell line LINCS IDap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/CLO_0000178

created byap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#created_by

creation dateap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#creation_date

curator noteap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000232

database_cross_referenceap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasDbXref

definitionap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/definition

definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/definition_citation

definition editorap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/definition_editor

e f o definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/EFO_definition_citation

e v definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/EV_definition_citation

external_definitionap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/UBPROP_0000001

f bbt definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/FBbt_definition_citation

f m a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/FMA_definition_citation

g a i d definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/GAID_definition_citation

galen definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/galen_definition_citation

has alternative idap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/hasAlternativeId

has associated axiom(fol)ap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000602

has db xrefap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/hasDbXref

has definitionap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasDefinition

has exact synonymap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/hasExactSynonym

has literature mining keywordsap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/INO_0000006

has o b o namespaceap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/hasOBONamespace

has related synonymap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/hasRelatedSynonym

has_alternative_idap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasAlternativeId

has_broad_synonymap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasBroadSynonym

has_exact_synonymap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasExactSynonym

has_narrow_synonymap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym

has_obo_namespaceap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasOBONamespace

has_rankap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/ncbitaxon#has_rank

has_related_synonymap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym

has_relational_adjectiveap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/UBPROP_0000007

i a o 0000231ap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000231

idap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#id

IEDB alternative termap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_9991118

in_subsetap back to ToC or Annotation Property ToC

IRI: http://www.geneontology.org/formats/oboInOwl#inSubset

is direct form ofap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002575

is indirect form ofap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002579

ISA alternative termap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0001847

m a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/MA_definition_citation

m a t definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/MAT_definition_citation

m e s h definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/MESH_definition_citation

m i a a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/MIAA_definition_citation

MPIO user-centered definitionap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000001

n c i thesaurus definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation

OBO foundry unique labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000589

pageap back to ToC or Annotation Property ToC

IRI: http://xmlns.com/foaf/0.1/page

s n o m e d c t definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/SNOMEDCT_definition_citation

STR profileap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/CLO_0037192

t a d s definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/TADS_definition_citation

t a o definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/TAO_definition_citation

Unique Apollo Labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/apollo_sv.owl/APOLLO_SV_0000040

w bbt definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/WBbt_definition_citation

wikipedia definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/Wikipedia_definition_citation

x a o definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/XAO_definition_citation

z f a definition citationap back to ToC or Annotation Property ToC

IRI: http://www.ebi.ac.uk/efo/ZFA_definition_citation

Namespace Declarations back to ToC

default namespace
http://purl.obolibrary.org/obo/dideo.owl#
2014-05-03
http://purl.obolibrary.org/obo/bfo/2014-05-03/
2017-03-24
http://purl.obolibrary.org/obo/iao/2017-03-24/
2023-10-16
http://purl.obolibrary.org/obo/dideo/release/2023-10-16/
apollo_sv
http://purl.obolibrary.org/obo/apollo_sv.owl/
chebi
http://purl.obolibrary.org/obo/chebi#
core
http://purl.obolibrary.org/obo/uberon/core#
dc
http://purl.org/dc/elements/1.1/
details
http://www.snomedbrowser.com/Codes/Details/
docs
http://purl.obolibrary.org/obo/ro/docs/
efo
http://www.ebi.ac.uk/efo/
evs
http://ncicb.nci.nih.gov/xml/owl/EVS/
foaf
http://xmlns.com/foaf/0.1/
go
http://purl.obolibrary.org/obo/go#
id
http://linkedlifedata.com/resource/umls/id/
ncbitaxon
http://purl.obolibrary.org/obo/ncbitaxon#
nifstd
http://uri.neuinfo.org/nif/nifstd/
obo
http://purl.obolibrary.org/obo/
oboInOwl
http://www.geneontology.org/formats/oboInOwl#
owl
http://www.w3.org/2002/07/owl#
pdro-owl
http://purl.obolibrary.org/obo/PDRO/PDRO.owl#
protege
http://protege.stanford.edu/plugins/owl/protege#
pubmed
http://www.ncbi.nlm.nih.gov/pubmed/
rdf
http://www.w3.org/1999/02/22-rdf-syntax-ns#
rdfs
http://www.w3.org/2000/01/rdf-schema#
ro
http://purl.obolibrary.org/obo/ro/
ro-owl
http://www.obofoundry.org/ro/ro.owl#
subsets
http://purl.obolibrary.org/obo/ro/subsets#
terms
http://purl.org/dc/terms/
uberon
http://purl.obolibrary.org/obo/uberon#
uo
http://purl.obolibrary.org/obo/uo#
wiki
http://ontologydesignpatterns.org/wiki/
xsd
http://www.w3.org/2001/XMLSchema#

This HTML document was obtained by processing the OWL ontology source code through LODE, Live OWL Documentation Environment, developed by Silvio Peroni .